Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
Introduction: The Kingdom of Saudi Arabia was one of the first countries to implement a COVID-19 vaccination program. This study estimated the safety and reactogenicity of the ChAdOx1-S vaccine after the first dose administered to adults. Methods: This cross-sectional study included 1592 randomly se...
Main Authors: | Salma Al Bahrani, Ali Albarrak, Othman Ali Alghamdi, Mesfer Abdullah Alghamdi, Fatimah H. Hakami, Asmaa K. Al Abaadi, Sausan A. Alkhrashi, Mansour Y. Alghamdi, Meshael M. Almershad, Mansour Moklif Alenazi, Mohamed Hany El Gezery, Arulanantham Zechariah Jebakumar, Jaffar A. Al-Tawfiq |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-09-01
|
Series: | International Journal of Infectious Diseases |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1201971221006081 |
Similar Items
-
Using the Bradford-Hill criteria to assess causality in the association between CHADOX1 NCOV-19 vaccine and thrombotic immune thrombocytopenia
by: C Raina MacIntyre
Published: (2021-04-01) -
How did AstraZeneca match actors, resources and activities to develop network relationship into Egyptian market?
by: Soliman, Tamer
Published: (2011) -
An observational study of breakthrough SARS-CoV-2 Delta variant infections among vaccinated healthcare workers in Vietnam
by: Nguyen Van Vinh Chau, et al.
Published: (2021-11-01) -
Adverse Effects of the COVID-19 Vaccine Reported by Lecturers and Staff of Kabul University of Medical Sciences, Kabul, Afghanistan
by: Azimi M, et al.
Published: (2021-10-01) -
Antibody Response against SARS-CoV-2 Following ChAdOx1(Astezeneca AZD 1222) Vaccine in Health Care Workers in a Tertiary Care Hospital in India
by: Felice FAIZAL, et al.
Published: (2021-09-01)